Arterra Bioscience Spa · MIL:ARBS
Arterra Bioscience Spa — Euronext Growth Conference 2022
34 slides from Arterra Bioscience Spa's conference presentation, May 24, 2022
Slide 1: Euronext Growth Conference May 24th, 2022
Euronext Growth Conference May 24th, 2022
Slide 2: Index of Topics
INDEX TO PI C S • ARTERRA AT GLANCE • POST IPO (2020-2022) MARKET CONSOLIDATION & DIVERSIFICATION • FINANCIALS
Slide 3: People Speaking Today
People Speaking Today M. GABRIELLA COLUCCI GUALTIERO IOIMO Founder, President and CEO CFO and Investor Relations Manager
Slide 4: Arterra Bioscience - Innovative SME
Arterra Bioscience - Innovative SME Arterra Bioscience Is a biotech company listed on the “Euronext Growth Milan” market of Borsa Italiana since 2019, founded in Naples by M. Gabriella Colucci in 2004 with the aim of developing technologies and innovative solutions that find application in various i
Slide 5: A Bit of History
A Bit of History Arterra Bioscience started its activity in 2004 as a spin-off of Arena Pharmaceuticals Inc. and based its research group in an incubator laboratory in Naples WHY NAPLES? Accredited Universities and Research Centers EU Support fo Research South of Italy is part of the convergence Com
Slide 6: Biotech and its potential
Biotech and its potential BIOTECHNOLOGY BLUE GREEN WHITE RED FOR THE BIOTECH BIOTECH BIOTECH BIOTECH RESEARCH AND THE marine and agricultural raw materials gene to DEVELOPMENTOF fresh water processes and to valuable drug NEW ACTIVE organisms plants products discovery COMPOUNDS TESTING DISCOVERY PLAT
Slide 7: Our Business Model
Our Buisiness Model Research Grants ResearchContracts Scientific Breakthrough New Technology Market needs RESEARCHIDEA INTERNAL SCIENTIFIC AGRIFOOD COSMETICS COMMITTEE AGRICULTURE NUTRACEUTICAL NUTRACEUTICAL Production & MEDICAL DEVICES Licence IP sales EXPERIMENTATION to Third Party INTERNAL COMMIT
Slide 8: Our Business Model: Vitalab
Our Business Model: A Born in 2010 Vitalab srl, a joint venture between Arterra Bioscience and Intercos Sells ingredients Arterra Bioscience for Cosmetic End markets application through
Slide 9: Main Scientific Achievements & Prizes
Main Scientific Achievements & Prizes 16 GRANTS 22 PATENTS 3 DEPOSITED 44 SCIENTIFIC ARTICLES 60 INNOVATIVE Approved and financed Inventor/co-inventor of 17 patents: TRADEMARK Co-author of 30 scientific articles on PRODUCTS Peer Reviewed Journals for a total projects’ value of N° 7 Worldwide Patents
Slide 10: A successful IPO
A successful IPO Key Statistics at IPO Date
Slide 11: Diversification Phase
Use of Proceeds • Integrate new technologies given the possibility of hiring highly qualified scientists coming from different areas of R&D biological sciences • Several R&D projects related to new products for Cosmetics, Nutraceutical, etc. CAPEX • New production equipment aimed at increasing the p
Slide 12: Post IPO 2020-2022
POST IPO 2020-2022 Euronext Growth Conference May 24th, 2022
Slide 13: Ownership & Company Structure
Ownership & Company Structure Main Shareholders Ing. Giuseppe Ferrante Dr. Gualtiero Ioimo Production Director & CFO, IR Manager & Board member Board member Gabriella Colucci Paolo Colucci 27.9% 7.5% Prof. Lucio Annunziato Indipendent Board member Industrial Shareholders Employees 8.7% 20 34 8 14 28
Slide 14: R&D Team
R&D Team Production and R&D team 1 11 11 7 Chem. Ing. PhD' s MSc Lab technician Post IPO new expertise: Scientific Director: PhD, Prof. WUR Production Director: Chemical Engineer Biochemist: Experienced PhD Synthetic Biology: Experienced PhD Chemistry : Experienced MSc The number does not include th
Slide 15: Management Team
Management Company Team Structure Post-IPO Gabriella Colucci Gualtiero Ioimo Vincenzo Fogliano Giuseppe Ferrante Marida Bimonte Annalisa Tito CEO CFO CSO COO Grant & IP Cell & Mol Biol. & Investor Relations Director Director
Slide 16: Company Organization
Company Organization President & CEO Gabriella Colucci CFO and Investor Relations Manager Executive Assistant Gualtiero Ioimo Alexandra Fellermeier Quality Control Scientific Coordinator Luigi Sena Vincenzo Fogliano Vitalab: Marketing Sales & Regulatory Production Director Grant & IP Office Director
Slide 17: Research Units
Research Units Chemistry Plant Biology Extraction RU Lyophilizati Histology on Molecular & Cell Biology
Slide 18: Research Units - Case study: Vita AvoCare
Research Units - Case study Intercos Vitalab Regulatory MT Stability Sourcing Extraction Chemistry Molecular Histology Clinical Test Marketing Biology Vita AvoCare 3 months research project
Slide 19: Capex
Capex Total Investment: 1.6 M New Chemistry lab New Growing capability Update Production lab Update Cell Biol Lab
Slide 20: Certifications
Certifications EFfCI CERTIFIED MIXED
Slide 21: Production Capabilities
Production Capabilities Fulfilled orders Productivity Productivity Outsourcing Year (kg) kg/day Euro/day (Euro) Cell Culture Lyophilization 2019 8860 9 3150 147.800 8.800 2020 9117 21 7350 272.636 8.000 2021 E. 14.500 21 7350 14.400 20.000 2022 50 17.500
Slide 22: M&A
M&A To enhance the competitive advantage of ARTERRA ARTERRA ADL Research Clinical Study Development Regulatory Active Ingr. Prod. Sale network
Slide 23: Business Consolidation
Business Consolidation Innovation in COSMETICS - 2020-2022 New Products on the Market NC55 Vita Ray-Immune NC56 Anchoryl Vita NC57 Vita Adren-Align Pelargonium capitatum stem cells Scabiosa arvensis stem cells Ficus carica stem cells NC59 Vita BotaniGuard. NC60 Vita Up-Gravity NC61 Vita Avocare: Pun
Slide 24: Business Consolidation: Scientific Publications
Business Consolidation Innovation in COSMETICS - 2020-2022 Scientific Publications • Ceccacci S, et al. An Oenothera biennis Cell Cultures Extract Endowed with Skin Anti-Ageing Activity Improves Cell Mechanical Properties. Metabolites 2021, 11, 527.. • Apone F. Uses and properties of bioactive pepti
Slide 25: Business Consolidation: Patents and Grants
Business Consolidation Innovation in COSMETICS - 2020-2022 Patents • 102020000021994. Uso cosmetico di estratti derivati da colture cellulari appartenenti alla specie Oenothera biennis e composizioni cosmetiche che contengono tali estratti. • 102019000021324. Uso cosmetico di un estratto derivato da
Slide 26: Business Diversification: Medical Device
Business Diversification Innovation in MEDICAL DEVICE - 2020-2022 Scientific Publications Tito A, Et Al. Pomegranate Peel Extract as an Inhibitor of SARS-CoV-2 Spike Binding to Human ACE2 Receptor (in vitro): A Promising Source of Novel Antiviral Drugs. Front Chem. 2021 Apr 28;9:638187 A pomegranate
Slide 27: Business Diversification
Business Diversification First product on the medical device market
Slide 28: Business Diversification: Medical Device & Nutraceutical
Business Diversification MEDICAL DEVICE & NUTRACEUTICAL Grant NUTRABEST - Fondo Crescita Sostenibile “Agrifood”, DM 5.3.2018, (Gennaio 2020 -Gennaio 2023) - Sviluppo di piattaforme molecolari e cellulari per l’identificazione di prodotti innovativi ad attività NUTRAceutica da Biotrasformazioni media
Slide 29: Business Diversification: Agrifood
Business Diversification AGRIFOOD June 2021 Arterra Bioscience and Montecarlofruit S.a.r.l., specialized in the production of aseptic mango fruit purea for baby food, in Mali, signed a research agrement for the up-cycling of the mango waste.
Slide 30: Financials
FINANCIALS Euronext Growth Conference May 24th, 2022
Slide 31: Limited production costs driving compelling profitability
Limited production costs driving compelling profitability: thriving upside arising from additional revenues to be mostly converted in EBITDA Turnover (€/000) Ebitda Adj (€/000) Net Income (€/000) 39,7% 43,3% 4.608 4.309 1,709 1,995 3.627 136 917 25,7% 35,1% 119 24,1% 1,351 37,0% 1,109 23,6% 1,111 79
Slide 32: First quarter of 2022 shows significant increase in turnover
The first quarter of 2022 has shown a significative increase in turnover Turnover (€/000) Net Debt (€/000) 2019 2020 2021 Cash and Cash Equivalents (4.669) (4.536) (4.814) 1.030 Current Financial 838 Receivables (340) 139 Current Financial Debt 214 218 223 128 Current Net Debt (4.455) (4.658) (4.591
Slide 33: Key Highlights
Key Highlights Bioscience great momentum since environmental 1 sustainability is becoming crucial for a huge number of industries Biotech company with an outstanding 2 R&D and highly qualified Technology Team A global reach and presence with low 3 commercial investments 4 Huge potential in the refer
Slide 34: Thanks
THANKS Euronext Growth Conference May 24th, 2022